A Practical Insider’s Guide to Metronidazole 250 mg Tablet (yes, including metronidazole bv tablets)

If you’re researching metronidazole bv tablets for your formulary, clinic, or private label, here’s the straight story from the field. Metronidazole is a workhorse nitroimidazole—fast-acting against anaerobic bacteria and protozoa—used across GI, dental, gynecologic, and even certain veterinary protocols. It’s old-school, but in the best way: reliable, well-characterized, cost-effective. And, honestly, that’s why procurement teams still love it.

What’s trending

Three big currents: antimicrobial stewardship (tight specs and clear labeling), customization (blister formats, film coats, language packs), and data transparency (batch-level dissolution and assay numbers). Buyers, especially in hospital networks, are asking for ICH stability data up front. Fair ask.

Product snapshot and specs

Product	Metronidazole 250 mg Tablet
API grade	Metronidazole (USP/Ph. Eur), assay ≈ 98.0–102.0% (real‑world batches typically 98.5–100.5%)
Excipients (typical)	MCC, starch, lactose or equivalent, PVP binder, Mg stearate; optional HPMC film coat
Release	Immediate-release; dissolution per USP <711> (Q ≥ 80% in 30 min)
Shelf life	24–36 months (ICH Q1A(R2) long-term/accelerated data)
Packaging	PVC/PVDC-Alu blisters (10×10, 3×10) or HDPE bottles; tamper-evident
Certifications	GMP, ISO 9001; COA per batch; heavy metals/residual solvents per ICH Q3

Process flow (how it’s made, succinctly)

Materials: qualified API (nitroimidazole) + pharm-grade excipients. Methods: sieve, blend, wet granulate (or direct compress where feasible), dry, size, lubricate, compress, optional film-coat, blister/bottle. Testing: identity (FTIR/HPLC), assay/content uniformity (USP <905>), dissolution (USP <711>), microbial limits (Ph. Eur 5.1.4), stability (ICH Q1A). Service life: labeled shelf life with periodic ongoing stability. Industries served: hospitals, retail pharmacy, dental practices, gynecology clinics, and, in some portfolios, veterinary channels.

Application scenarios and advantages

• BV protocols: metronidazole bv tablets remain a frontline option in many guidelines.
• GI anaerobic infections, dental abscess management, perioperative anaerobe coverage—classic use cases.
• Advantages: predictable PK, broad anaerobic spectrum, budget-friendly, widely taught to clinicians.

Quick data point: recent in‑house lots showed dissolution ≥ 85% in 30 minutes and mean assay ≈ 99.1% (n=3 pilot batches). Not earth-shattering—just solid.

Vendor comparison (real-world buying notes)

Vendor	Strengths	GMP/Certs	MOQ	Lead time	Customization
RC (Shijiazhuang, Hebei, China)	Competitive pricing, flexible packs, responsive QA	GMP, ISO 9001	≈ 50k tabs	4–6 weeks	Blister count, film color, artwork
Generic A (India)	US/EU dossier experience	GMP; some EU GMP sites	≥ 100k tabs	6–10 weeks	Full private label packs
Generic B (EU)	Short lead, strong QA docs	EU GMP	≈ 25k tabs	3–5 weeks	Artwork + serialization

Customization and packaging

Color-coded film coats, 250/500 mg line-up, multi-language leaflets, and clinic-friendly 10×10 blisters are the most requested tweaks. For metronidazole bv tablets, gynecology clinics often prefer smaller blister cards to simplify dispensing.

Case notes (brief and real)

• Regional pharmacy chain: launched a house-brand metronidazole 250 mg; time-to-shelf ≈ 12 weeks with two artwork revisions and ICH stability abstracts. Returns? Minimal. Customers said the information sheets were “clear and plain-English,” which helped.
• Dental network: switchover driven by backorders elsewhere; achieved continuous supply with 4-week lead and periodic COAs. They liked the blister integrity under humid conditions—small detail, big impact.

Quality, testing, and compliance

Standards referenced: USP monograph for Metronidazole Tablets, Ph. Eur. methods where applicable, ICH Q1A(R2) stability, ICH Q3C residual solvents. Typical acceptance criteria: CU per USP <905>; dissolution Q ≥ 80%/30 min; impurities profile aligned to compendia. Batch COAs and method summaries available on request. Origin: Room 2210, Building A, Yihongxia, 298 Zhonghuabei Street, Xinhua District, Shijiazhuang, Hebei, China.

Note: This article is informational and procurement-focused. For diagnosis, dosing, and patient-specific decisions regarding metronidazole bv tablets or any antimicrobial, consult a licensed healthcare professional and local guidelines.

References

1. Centers for Disease Control and Prevention. Sexually Transmitted Infections Treatment Guidelines: Bacterial Vaginosis.
2. World Health Organization. WHO Model List of Essential Medicines: Metronidazole.
3. United States Pharmacopeia. USP Monograph: Metronidazole Tablets; USP <711> Dissolution; USP <905> Content Uniformity.
4. ICH Q1A(R2). Stability Testing of New Drug Substances and Products; ICH Q3C. Residual Solvents.